Jianrong Wu

8.0k total citations
158 papers, 4.5k citations indexed

About

Jianrong Wu is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Neurology. According to data from OpenAlex, Jianrong Wu has authored 158 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Pulmonary and Respiratory Medicine, 41 papers in Molecular Biology and 38 papers in Neurology. Recurrent topics in Jianrong Wu's work include Neuroblastoma Research and Treatments (36 papers), Sarcoma Diagnosis and Treatment (34 papers) and Statistical Methods in Clinical Trials (22 papers). Jianrong Wu is often cited by papers focused on Neuroblastoma Research and Treatments (36 papers), Sarcoma Diagnosis and Treatment (34 papers) and Statistical Methods in Clinical Trials (22 papers). Jianrong Wu collaborates with scholars based in United States, Australia and China. Jianrong Wu's co-authors include Peter J. Houghton, Catherine A. Billups, Malcolm A. Smith, John M. Maris, Stephen T. Keir, E. Anders Kolb, Najat C. Daw, C. Patrick Reynolds, Christopher L. Morton and Richard Görlick and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Journal of the American Statistical Association.

In The Last Decade

Jianrong Wu

156 papers receiving 4.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jianrong Wu United States 38 1.6k 1.5k 1.4k 991 571 158 4.5k
Massimo Barberis Italy 38 1.5k 0.9× 849 0.6× 1.9k 1.4× 604 0.6× 884 1.5× 204 4.2k
Thomas Filleron France 33 1.4k 0.9× 1.1k 0.8× 2.1k 1.6× 283 0.3× 808 1.4× 222 4.9k
Niels Willi Switzerland 24 1.7k 1.1× 1.5k 1.0× 1.7k 1.2× 483 0.5× 623 1.1× 45 4.7k
Marco Lucchi Italy 45 2.3k 1.4× 1.8k 1.2× 1.8k 1.3× 2.0k 2.0× 919 1.6× 224 6.5k
Sarah Dry United States 47 2.3k 1.4× 1.3k 0.8× 2.4k 1.7× 707 0.7× 598 1.0× 197 7.2k
Lia Gore United States 43 821 0.5× 2.6k 1.7× 2.6k 1.9× 537 0.5× 632 1.1× 202 6.1k
Andrea Abati United States 38 945 0.6× 1.1k 0.8× 1.9k 1.4× 341 0.3× 465 0.8× 97 4.6k
Cynthia Cohen United States 37 931 0.6× 1.5k 1.0× 1.5k 1.1× 212 0.2× 774 1.4× 139 4.3k
Antonino Maiorana Italy 33 975 0.6× 675 0.5× 2.0k 1.4× 315 0.3× 488 0.9× 197 3.9k
Antonio Llombart‐Bosch Spain 43 3.4k 2.1× 1.8k 1.2× 1.8k 1.3× 832 0.8× 1.0k 1.8× 294 6.7k

Countries citing papers authored by Jianrong Wu

Since Specialization
Citations

This map shows the geographic impact of Jianrong Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianrong Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianrong Wu more than expected).

Fields of papers citing papers by Jianrong Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jianrong Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianrong Wu. The network helps show where Jianrong Wu may publish in the future.

Co-authorship network of co-authors of Jianrong Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Jianrong Wu. A scholar is included among the top collaborators of Jianrong Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jianrong Wu. Jianrong Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ragab, Ahmed, Jianrong Wu, Xue Ding, et al.. (2020). 68Ga-DOTATATE PET/CT: The Optimum Standardized Uptake Value (SUV) Internal Reference. Academic Radiology. 29(1). 95–106. 5 indexed citations
2.
Fernández‐Pineda, Israel, et al.. (2018). Modified Uniportal Video-Assisted Thoracic Surgery Versus Three-Port Approach for Lung Nodule Biopsy in Pediatric Cancer Patients. Journal of Laparoendoscopic & Advanced Surgical Techniques. 29(3). 409–414. 7 indexed citations
3.
Nguyen, Rosa, M. Beth McCarville, April Sykes, et al.. (2018). Rapid decrease of serum alpha-fetoprotein and tumor volume predicts outcome in children with hepatoblastoma treated with neoadjuvant chemotherapy. International Journal of Clinical Oncology. 23(5). 900–907. 9 indexed citations
4.
Federico, Sara M., M. Beth McCarville, Barry L. Shulkin, et al.. (2017). A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma. Clinical Cancer Research. 23(21). 6441–6449. 114 indexed citations
5.
Mao, Shenghua, Amos Hong Pheng Loh, John A. Sandoval, et al.. (2016). Operative and Immediate Postoperative Differences Between Traditional Multiport and Reduced Port Laparoscopic Total Splenectomy in Pediatric Patients. Journal of Laparoendoscopic & Advanced Surgical Techniques. 27(2). 206–210. 5 indexed citations
6.
Anghelescu, Doralina L., et al.. (2016). Mirror Therapy for Phantom Limb Pain at a Pediatric Oncology Institution. Rehabilitation Oncology. 34(3). 104–110. 24 indexed citations
7.
Wu, Jianrong. (2016). Single-Arm Phase II Survival Trial Design Under the Proportional Hazards Model. Statistics in Biopharmaceutical Research. 9(1). 25–34. 6 indexed citations
8.
Interiano, Rodrigo B., Alpin D. Malkan, Amos Hong Pheng Loh, et al.. (2016). Initial diagnostic management of pediatric bone tumors. Journal of Pediatric Surgery. 51(6). 981–985. 10 indexed citations
9.
Guo, Junyu, John O. Glass, M. Beth McCarville, et al.. (2015). Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI. British Journal of Cancer. 113(9). 1282–1288. 26 indexed citations
10.
Interiano, Rodrigo B., et al.. (2015). Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors. Journal of Pediatric Surgery. 50(9). 1484–1489. 30 indexed citations
11.
Turner, David C., Fariba Navid, Najat C. Daw, et al.. (2014). Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing. Clinical Cancer Research. 20(10). 2783–2792. 40 indexed citations
12.
Federico, Sara M., Heather Allewelt, Sheri L. Spunt, et al.. (2014). Subsequent Malignant Neoplasms in Pediatric Patients Initially Diagnosed With Neuroblastoma. Journal of Pediatric Hematology/Oncology. 37(1). e6–e12. 19 indexed citations
13.
Wu, Jianrong. (2014). Power and Sample Size for Randomized Phase III Survival Trials Under the Weibull Model. Journal of Biopharmaceutical Statistics. 25(1). 16–28. 16 indexed citations
14.
Hu, Huimin, Elida Gomero, Erik Bonten, et al.. (2011). Preclinical Dose-Finding Study With a Liver-Tropic, Recombinant AAV-2/8 Vector in the Mouse Model of Galactosialidosis. Molecular Therapy. 20(2). 267–274. 27 indexed citations
15.
Morton, Christopher L., John M. Maris, Stephen T. Keir, et al.. (2011). Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. Pediatric Blood & Cancer. 58(4). 566–571. 24 indexed citations
16.
Görlick, Richard, E. Anders Kolb, Peter J. Houghton, et al.. (2009). Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatric Blood & Cancer. 53(4). 594–598. 26 indexed citations
17.
Houghton, Peter J., Christopher L. Morton, E. Anders Kolb, et al.. (2007). Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatric Blood & Cancer. 50(1). 37–45. 98 indexed citations
18.
Weiss, Aaron R., Joseph D. Khoury, Fredric A. Hoffer, et al.. (2007). Telangiectatic osteosarcoma: The St. Jude Children's Research Hospital's experience. Cancer. 109(8). 1627–1637. 49 indexed citations
19.
Ganti, Ramapriya, Stephen X. Skapek, Jie Zhang, et al.. (2006). Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. Modern Pathology. 19(9). 1213–1220. 68 indexed citations
20.
Wu, Jianrong, Guoyong Jiang, Augustine Wong, & Xiang Sun. (2002). Likelihood Analysis for the Ratio of Means of Two Independent Log-Normal Distributions. Biometrics. 58(2). 463–469. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Massimo Barberis Breakdown of academic impact, for papers by Thomas Filleron Breakdown of academic impact, for papers by Niels Willi Breakdown of academic impact, for papers by Marco Lucchi Breakdown of academic impact, for papers by Sarah Dry Breakdown of academic impact, for papers by Lia Gore Breakdown of academic impact, for papers by Andrea Abati Breakdown of academic impact, for papers by Cynthia Cohen Breakdown of academic impact, for papers by Antonino Maiorana Breakdown of academic impact, for papers by Antonio Llombart‐Bosch
Rankless by CCL
2026